Antibody Discovery Market Report 2026

The antibody discovery market size has grown strongly in recent years. It will grow from $9.78 billion in 2025 to $10.75 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased r&d investments in antibody discovery, rising prevalence of infectious and chronic diseases, advances in hybridoma technology, government funding for biotechnology research, collaboration between academic institutions and pharma,.

The antibody discovery market size is expected to see rapid growth in the next few years. It will grow to $15.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to growth in personalized medicine demand, adoption of ai and ml in drug discovery, expansion of biologics market, integration of high-throughput screening platforms, rising focus on immunotherapy and targeted therapies. Major trends in the forecast period include high-throughput screening techniques, monoclonal antibody advancements, personalized antibody therapeutics, multi-specific antibody development, synthetic antibody engineering.

The increasing demand for precision therapeutics is expected to drive the growth of the antibody discovery market in the coming years. Precision therapeutics, also called personalized therapeutics, involves tailoring medical treatment plans and interventions to the unique characteristics of individual patients. Antibody discovery supports precision therapeutics by enabling the development of targeted therapies, such as monoclonal antibodies, that interact specifically and precisely with disease-related molecules or cells, resulting in more effective and personalized treatment. For instance, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare sectors, reported that global spending on cell and gene therapies reached $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the rising need for precision therapeutics is fueling growth in the antibody discovery market.

Major companies in the antibody discovery market are developing innovative technologies, such as AI-based computational antibody drug discovery platforms, to enhance the efficiency and accuracy of antibody development. An AI-based computational antibody drug discovery platform leverages artificial intelligence and computational techniques to accelerate the identification and optimization of therapeutic antibodies. For instance, in October 2023, SwiftPharma BV, a Belgium-based company specializing in recombinant proteins from a plant-based system, launched an AI-driven antibody discovery platform. This advanced platform integrates artificial intelligence, big data, machine learning, and phage display techniques to quickly predict high-specificity and high-affinity antibody-antigen interactions. Functioning similarly to natural language processing, the system generates diverse antibody variants, enabling SwiftPharma to efficiently create extensive antibody libraries. This technology significantly accelerates the discovery of potential antibody therapies.

In July 2024, Pentixapharm, a Germany-based radiopharmaceutical biotechnology company, acquired Glycotope’s target discovery unit for an undisclosed amount. The acquisition supports Pentixapharm’s strategy to expand its oncology pipeline by converting preclinical antibodies targeting multiple cancer antigens into radiopharmaceuticals. In addition to the preclinical assets, Pentixapharm gained Glycotope’s laboratories, cell banks, tumor target database, and equipment, further strengthening its intellectual property portfolio beyond the CXCR4 receptor. Glycotope is a Germany-based biotechnology company focused on developing glyco-optimized antibodies for cancer immunotherapy.

Major companies operating in the antibody discovery market are Charles River Laboratories, WuXi Biologics, Genmab A/S, Evotec, ChemPartner, Aragen Life Science Pvt. Ltd., GenScript Technology Corporation, Biocytogen, Twist Bioscience, BioDuro-Sundia, Fairjourney Biologics S.A., Harbour BioMed, Rockland Immunochemicals, Creative Biolabs, Synbio Technologies, ImmunoPrecise, Ablexis, Myrio Therapeutics, Antibody Solutions, MabSilico.

North America was the largest region in the antibody discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antibody discovery market by increasing the cost of importing laboratory equipment, reagents, and raw materials, thereby affecting R&D timelines and operational budgets. Regions such as North America and Europe, which rely on imports for high-end screening instruments and biotechnology components, are particularly impacted. Segments including high-throughput screening and synthetic antibody development face higher costs, potentially slowing research and production. However, tariffs have also encouraged local manufacturing and supply chain diversification, promoting innovation and resilience in the market.

The antibody discovery market research report is one of a series of new reports that provides antibody discovery market statistics, including antibody discovery industry global market size, regional shares, competitors with a antibody discovery market share, detailed antibody discovery market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery industry. This antibody discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibody discovery is the process of identifying and developing antibodies, which are proteins produced by the immune system to protect the body against harmful agents, such as bacteria and viruses. Antibodies, also called immunoglobulins, are essential to the immune response as they recognize and bind to specific molecules known as antigens.

The main methods used in antibody discovery include phage display, hybridoma, and others. Phage display is a molecular biology technique used to study and select peptides or proteins, often antibodies, that bind with high affinity to a specific target. It is widely used in antibody discovery to generate and identify antibodies with precise binding characteristics. The types of antibodies include humanized antibodies, human antibodies, chimeric antibodies, and murine antibodies, which are utilized by end users in the pharmaceutical and biotechnology sectors, research laboratories, and academic institutions.

The antibody discovery market includes revenues earned by entities by providing services such as antigen identification, immunization, antibody generation, screening, and characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody discovery market also includes sales of antibody libraries, phage display kits, antigen proteins, and antibody screening platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.